The P-IIb study evaluating Rinvoq in adults with NSV. The trial met the 1EPs of percent change from baseline in F-VASI at 24wk. with the 11 & 22mg doses, percent reduction from baseline in F-VASI at 52wk. was numerically greater than the results at 24wk.
At 24wk., percent CFB in F-VASI at upadacitinib 6, 11 & 22mg doses (-22.0, -35.6 & -34.0 vs -14.4), higher response rates were observed in 2EPs incl. F-VASI 75 (8.2%, 19.1% & 14.0% vs 2.2%) and T-VASI 50 (6.1%, 6.4% & 11.6% vs 2.2%). At 52wk. percent CFB in F-VASI (-52.3, -62.8 & -59.2); F-VASI 75 (28.6%, 51.1% & 25.6%); T-VASI 50 (24.5%, 31.9% & 27.9%), respectively
No new safety signals were seen, and treatment discontinuation due to TEAEs was observed in the upadacitinib (22mg) over the other groups
Ref: AbbVie | Image: AbbVie
Related News:-
AbbVie Presents P-III (Measure Up 1), (Measure Up 2) and (AD Up) Studies Results of Rinvoq for Atopic Dermatitis at 32nd EADV Congress 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
